Syndax Pharmaceuticals Inc·4

Feb 5, 4:21 PM ET

Meyers Michael L. 4

4 · Syndax Pharmaceuticals Inc · Filed Feb 5, 2021

Insider Transaction Report

Form 4
Period: 2021-02-03
Meyers Michael L.
SVP, Chief Development Officer
Transactions
  • Other

    Common Stock

    2020-07-31$7.97/sh+2,665$21,24013,395 total
  • Other

    Common Stock

    2021-01-31$12.00/sh+1,771$21,25215,166 total
  • Award

    Stock Option (Right to Buy)

    2021-02-03+80,00080,000 total
    Exercise: $21.36Exp: 2031-02-03Common Stock (80,000 underlying)
Footnotes (3)
  • [F1]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 2,665 shares by the Reporting Person on 07/31/2020 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F2]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,771 shares by the Reporting Person on 01/31/2021 pursuant to the Issuer's Employee Stock Purchase Plan.
  • [F3]1/48th of the shares subject to the option shall vest monthly over a four-year period.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT